Exscientia Plc reported 630.77M in Market Capitalization this January of 2025, considering the latest stock price and the number of outstanding shares.Data for Exscientia Plc | EXAI - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last December in 2025.

This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.

Exscientia Plc reported 7.53M in Cost of Sales for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported 411.41M in Assets for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported 64K in Ordinary Share Capital for its fiscal quarter ending in June of 2024. Data for Exscientia Plc | EXAI - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported -32.69M in EBITDA for its fiscal quarter ending in June of 2024. Data for Exscientia Plc | EXAI - Ebitda including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported 21.39M in Debt for its fiscal quarter ending in June of 2024. Data for Exscientia Plc | EXAI - Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Non-traditional data signals from social media and employment platforms for EXAI stock analysis

Exscientia Plc reported 15.4M in Loan Capital for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Loan Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported -49.4M in EBIT for its fiscal quarter ending in June of 2024. Data for Exscientia Plc | EXAI - Ebit including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported 299.16M in Current Assets for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Current Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported 255.42M in Equity Capital and Reserves for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last December in 2025.

Exscientia Plc reported -52.13M in Net Income for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Net Income including historical, tables and charts were last updated by Trading Economics this last November in 2025.

Common-Stock-Shares-Outstanding Time Series for Sanofi SA. Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

The global drug discovery AI tools market is projected to reach USD 6407 million by 2033, growing at a CAGR of XX% during the forecast period of 2025-2033. The market is driven by factors such as increasing demand for personalized medicine, rising prevalence of chronic diseases, and advancements in AI technology. Key trends in the market include the growing adoption of AI-powered drug discovery platforms, the use of AI to identify new drug targets, and the development of AI-based tools for clinical trial optimization. Additionally, collaborations between pharmaceutical companies and AI startups are expected to accelerate the development and commercialization of AI-based drug discovery tools. Major companies in the market include Atomwise, BenevolentAI, Recursion, Exscientia, Insilico Medicine, Valo Health, Owkin, XtalPi, and Healx.

Exscientia Plc reported 57.48M in Operating Expenses for its fiscal quarter ending in September of 2024. Data for Exscientia Plc | EXAI - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last December in 2025.

The size of the AI in Precision Medicine Market market was valued at USD 2.86 Million in 2023 and is projected to reach USD 16.90 Million by 2032, with an expected CAGR of 28.89% during the forecast period. Recent developments include: February 2024: Exscientia PLC, an AI-driven precision medicine company, reported the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukemia (AML), to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response., June 2023: Dartmouth, an Ivy League research university, launched the Center for Precision Health and Artificial Intelligence (CPHAI) to advance interdisciplinary research into how artificial intelligence (AI) and biomedical data can be used to improve precision medicine and health outcomes.. Key drivers for this market are: Rising Demand for Precision Medications, Growing Adoption of Electronic Health Records. Potential restraints include: Rising Demand for Precision Medications, Growing Adoption of Electronic Health Records. Notable trends are: The Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period..

Stock Price Time Series for Sanofi SA. Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

The global AI Drug Development market is projected to reach a value of USD X.XX Million by 2033, exhibiting a CAGR of 5% during the forecast period (2025-2033). The increasing demand for personalized and targeted therapies, advancements in machine learning and computing power are driving the adoption of AI in drug development. Additionally, the need to reduce the time and costs associated with traditional drug discovery processes further fuels the market growth. Key market players include Insilico Medicine, Cyclica, XtalPi Inc., Exscientia Limited, AiCure, LLC, Atomwise, Biovista Inc., Breg, Inc., Numerate, Cloud Pharmaceuticals, IBM, NuMedii, BenevolentAI, and Lam Therapeutics, among others. The market is segmented by type (drug design, drug synthesis, others) and application (tumor, nervous system, others). Geographically, North America holds the largest market share due to the presence of major pharmaceutical companies and a favorable regulatory environment. Europe and Asia-Pacific are also expected to witness significant growth due to increasing investments in AI research and development.

The global AI-assisted Drug Design (AIDD) market is poised to grow exponentially, with a market size of $1786.8 million in 2025, projected to reach $13,778.1 million by 2033. This growth is fueled by a CAGR of 30.7% from 2025 to 2033. The increasing demand for faster and more efficient drug discovery processes, coupled with the growing adoption of artificial intelligence (AI) in healthcare, is driving this market's growth. Moreover, the rising prevalence of chronic diseases, the need for personalized medicine, and the increasing availability of high-throughput experimental data further contribute to the market's growth. The market is segmented into applications such as early drug discovery, preclinical phase, clinical phase, and regulatory approval. Furthermore, hardware, software, and service segments cater to the different types of AIDD solutions. Key players in the market include IBM, Exscientia, Google (Alphabet), Microsoft, and Atomwise, among others. The market is geographically distributed across North America, South America, Europe, the Middle East & Africa, and Asia Pacific. North America dominates the market, followed by Europe, due to the early adoption of AI technologies in these regions.